The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

CSL is a top pharmaceutical company based in Melbourne, Australia Read the full story

Vaccine maker and blood products specialist CSL in $950m share buyback. Read the full story

CSL is a large speciality biopharmaceutical company developing and manufacturing plasma products and vaccines to treat and protect patients worldwide. Read the full story

CSL has announced only 1 M&A deal since 2005, with the acquisition of Zenyth Therapeutics Read the full story

CSL is a global pharma company active in the development of vaccines and plasma proteins with a prime focus on influenza vaccine - partnering, collaborative R&D and licensing activity of CSL is reviewed here.

Read the full story

CSL, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

This report provides all the information you require to better understand CSL and its partnering interests and activities over the past seven years. Read the full story

It is a rare event to see a multi-billion dollar acquisition take place involving a company outside the bigpharma top 50. Read the full story

The six-year agreement with CSL Biotherapies, a division of CSL, calls for Merck to market Afluria in the United States, where it was approved by the Food and Drug Administration in 2007, starting next year. CSL will make the vaccine and maintain marketing and distribution rights in the rest of the world.